Lower pectoralis muscle area is associated with a worse overall survival in non-small cell lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 1, 2017, Pages 38-43

  Matthew Kinsey, C ^a   Estepar, Raul San Jose ^b   Van Der Velden, Jos ^c   Cole, Bernard F ^d   Christiani, David C ^e   Washko, George R ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

^d Harvard School of Public Health ^*  (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHRONIC BRONCHITIS; COMPUTED TOMOGRAPHY SCANNER; ELECTROCORTICOGRAPHY; EMPHYSEMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LOWER PECTORALIS MUSCLE AREA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PECTORAL MUSCLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; THORAX RADIOGRAPHY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY; ANALYSIS OF VARIANCE; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUSCLE ATROPHY; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCULAR ATROPHY; PECTORALIS MUSCLES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85009151540     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1067     Document Type: Article

References (26)

1. Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 2015;23:1699-708.
2. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004;90:1905-11.
3. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135-41.
4. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007;25:418-23.
5. Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, et al. Early recognition of malnutrition and cachexia in the cancer patient: A position paper of a European School of Oncology Task Force. Ann Oncol 2014;25:1492-9.
6. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-95.
7. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A populationbased study. Lancet Oncol 2008;9:629-35.
8. Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-9.
9. Prado CMM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-6.
10. Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJR, Goh V. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 2015;6:489-97.
11. Lukaski H. Sarcopenia: Assessment of muscle mass. J Nutr 1997;127: 994S-997S.
12. Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-43.
13. McDonald M-LN, Diaz AA, Ross JC, San Jose Estepar R, Zhou L, Regan EA, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A crosssectional study. Ann Am Thorac Soc 2014;11:326-34.
14. Kinsey CM, Estepar RSJ, Zhao Y, Yu X, Diao N, Heist RS, et al. Invasive adenocarcinoma of the lung is associatedwith the upper lung regions. Lung Cancer 2014;84:145-50.
15. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-62.
16. Kinsey CM, San Jose Estepar R, Wei Y, Washko GR, Christiani DC. Regional emphysema of a non-small cell tumor is associated with larger tumors and decreased survival rates. Ann Am Thorac Soc 2015;12:1197-205.
17. Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 2008;29:2147-52.
18. Lee BW, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. Association of cigarette smoking and asbestos exposure with location and histology of lung cancer. Am J Respir Crit Care Med 1998;157:748-55.
19. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced nonsmall-cell lung cancer. J Clin Oncol 2008;26:5596-602.
20. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897-906.
21. Diaz AA, Valim C, Yamashiro T, Estepar RSJ, Ross JC, Matsuoka S, et al. Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers. Chest 2010;138:880-7.
22. Diaz AA, Come CE, Ross JC, San Jose Estepar R, Han MK, Loring SH, et al. Association between airway caliber changes with lung inflation and emphysema assessed by volumetric CT scan in subjects with COPD. Chest 2012;141:736-44.
23. Wan ES, Hokanson JE, Murphy JR, Regan EA, Make BJ, Lynch DA, et al. Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. Am J Respir Crit Care Med 2011;184:57-63.
24. Diaz AA, Zhou L, Young TP, McDonald M-L, Harmouche R, Ross JC, et al. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. Acad Radiol 2014;21:1255-61.
25. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
26. Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest 2014;145:346-53.